TEL AVIV, Israel, Nov. 27, 2017 /PRNewswire/ -- Galmed
Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a
clinical-stage biopharmaceutical company focused on the development
of a once-daily, oral therapy for the treatment of nonalcoholic
steatohepatitis, or NASH and other liver diseases, today announced
that Dr. Carol L. Brosgart, Clinical
Professor of Medicine, Epidemiology and Biostatistics, University of California, San Francisco (UCSF), a
member of Galmed's board of directors, will present at the 22nd
biennial HEP DART meeting, to be held at Kona, Hawaii, December 3-7,
2017.
Dr. Brosgart's presentation entitled: "Aramchol for NASH and
beyond: From Scientific Rationale to Clinical Development" will
provide the foundations of the ARRIVE and ARREST clinical studies
which are expected to report topline data in the first and second
quarters of 2018, respectively.
Dr. Brosgart's Presentation Details:
Date: Thursday, December 7, 2017
Time: 09:00am HST
Location: Fairmont Orchid Hotel, Kona, Hawaii
About the HEP DART 2017 Meeting
The focus of HEP DART is to assemble clinicians, medical
professionals, nurses, researchers and basic scientists together to
advance knowledge of the ongoing drug development processes in the
treatment of viral hepatitis, NASH, and co-infections. HEP DART
meeting uniquely blend the areas of biology, chemistry,
pharmacology and clinical research to provide the scientific
community with an increased understanding of the current and future
challenges in hepatology (including viral hepatitis, NASH, and
co-infections).
About Aramchol™ and Non-alcoholic Steatohepatitis
(NASH)
Aramchol™ (arachidyl amido cholanoic acid) is a novel fatty acid
bile acid conjugate, inducing beneficial modulation of
intra-hepatic lipid metabolism. Aramchol™'s ability to modulate
hepatic lipid metabolism was discovered and validated in animal
models, demonstrating down regulation of the three key pathologies
of NASH: steatosis, inflammation and fibrosis. The effect of
Aramchol™ on fibrosis is mediated by down regulation of steatosis
and directly on human collagen producing cells. Aramchol™ has been
granted Fast Track designation status by the FDA for the treatment
of NASH.
NASH is an emerging world crisis impacting an estimated 3% to 5%
of the U.S. population and an estimated 2% to 4% globally. It is
the fastest growing cause of liver cancer and liver transplant in
the U.S. due to the rise in obesity. NASH is the progressive form
of non-alcoholic fatty liver disease that can lead to
cardiovascular disease, cirrhosis and liver-related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on
the development of Aramchol™, a first in class, novel, once-daily,
oral therapy for the treatment of NASH for variable populations, as
well as other liver associated disorders. Galmed is currently
conducting the ARREST Study, a multicenter, randomized, double
blind, placebo-controlled Phase IIb clinical study designed to
evaluate the efficacy and safety of Aramchol™ in 248 subjects with
NASH, who are overweight or obese, and who are pre-diabetic or
type-II-diabetic. Galmed also sponsors the ARRIVE Study, a
proof-of-concept Phase IIa clinical trial designed to evaluate the
safety and efficacy of Aramchol™ in 50 patients with HIV-associated
NAFLD and lipodystrophy. The ARRIVE Study is an
investigator-initiated trial, conducted at the University of California San Diego by Professor
Rohit Loomba. More information about
the ARREST Study and the ARRIVE Study may be found on
ClinicalTrials.gov identifiers: NCT02279524 and NCT02684591,
respectively.
View original
content:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-present-at-hep-dart-2017-meeting-300561715.html
SOURCE Galmed Pharmaceuticals Ltd.